PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1543685
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1543685
Global Anti-radiation Drugs Market Size study, by Compound, by Application, by Distribution Channel, and Regional Forecasts 2022-2032
The global Anti-radiation Drugs Market was valued at approximately USD 4.11 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 9.9% over the forecast period 2024-2032. Anti-radiation drugs offer protection against radiation exposure. These drugs include KI, Prussian Blue, and DTPA (Diethylenetriamine pentaacetate). Anti-radiation medicines help block the absorption and subsequent concentration of radioactive iodine in the thyroid gland. KI must be consumed before or shortly after exposure to radioactive iodine for better results. It is effective only against radioactive iodine and not against other types of radiation. Oxidation of ferrous ferrocyanide salts produces Prussian blue, which is used for the treatment of thallium poisoning or radioactive cesium poisoning.
The high prevalence of cancer and Acute Radiation Syndrome (ARS) is driving the anti-radiation drugs business. Potassium iodide (KI), an anti-radiation drug, provides some protection in cases of radiation exposure. The rise in concerns regarding the usage of nuclear weapons in wars is expected to augment the demand for anti-radiation pills. Detonation of a nuclear weapon may lead to the release of radioactive iodine. Biotechnology firms are receiving government contracts to develop drugs for the treatment of ARS. Vendors in the anti-radiation drugs sector are investing significantly in expanding their production capabilities. They are also launching new products to broaden their Anti-radiation Drugs Market share.
The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. North America is the dominating and fastest-growing region in the Anti-radiation Drugs Market. This leadership is driven by several key factors. The region's advanced healthcare infrastructure, coupled with significant government investments in defense and emergency preparedness, has spurred demand for anti-radiation drugs. The United States, in particular, has seen substantial funding directed towards stockpiling and research of these drugs as part of national security measures against potential nuclear threats or radiological emergencies. Additionally, the presence of leading pharmaceutical companies and research institutions in North America contributes to rapid advancements in drug development and commercialization. The increasing awareness of radiation risks, both from potential nuclear incidents and from medical radiation exposure, further boosts the market. Regulatory support and accelerated approval processes for emergency use drugs also play a crucial role in the region's dominance and fast-paced growth in the global Anti-radiation Drugs Market.
Major market players included in this report are:
- Amgen Inc.
- Anbex Inc.
- Arco Pharmaceuticals LLC
- BTG International Inc.
- Cellphire, Inc.
- Chrysalis BioTherapeutics, Inc.
- Darnitsa
- Enzychem Lifesciences Corporation
- Humanetics Corporation
- Mission Pharmacal Company
- Myelo Therapeutics GmbH
- Partner Therapeutics
- Pluri Inc.
- Jubilant Life Sciences Ltd.
The detailed segments and sub-segment of the market are explained below:
By Compound:
- Potassium Iodide (KI)
- Prussian Blue
- DTPA (Diethylenetriamine Pentaacetate)
- Others
By Application:
- Acute Radiation Syndrome (ARS)
- Cancer Treatment
- Radiation Exposure
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacifc
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Years considered for the study are as follows:
- Historical year - 2021-2022
- Base year - 2023
- Forecast period - 2022 to 2023
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Anti-radiation Drugs Market Executive Summary
- 1.1. Global Anti-radiation Drugs Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Compound
- 1.3.2. By Application
- 1.3.3. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Anti-radiation Drugs Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Anti-radiation Drugs Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Increase in Risk of Radiological and Nuclear Incidents
- 3.1.2. Rise in R&D of Radiopharmaceuticals
- 3.2. Market Challenges
- 3.2.1. High Cost of Drug Development
- 3.2.2. Regulatory Hurdles
- 3.3. Market Opportunities
- 3.3.1. Expansion in Emerging Markets
- 3.3.2. Investment in New Product Development
Chapter 4. Global Anti-radiation Drugs Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Anti-radiation Drugs Market Size & Forecasts by Compound 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Anti-radiation Drugs Market: Compound Revenue Trend Analysis, 2022 & 2032(USD Billion)
- 5.2.1. Potassium Iodide (KI)
- 5.2.2. Prussian Blue
- 5.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 5.2.4. Others
Chapter 6. Global Anti-radiation Drugs Market Size & Forecasts by Application 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Anti-radiation Drugs Market: Application Revenue Trend Analysis, 2022 & 2032(USD Billion)
- 6.2.1. Acute Radiation Syndrome (ARS)
- 6.2.2. Cancer Treatment
- 6.2.3. Radiation Exposure
- 6.2.4. Others
Chapter 7. Global Anti-radiation Drugs Market Size & Forecasts by Distribution Channel 2022-2032
- 7.1. Segment Dashboard
- 7.2. Global Anti-radiation Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospital Pharmacies
- 7.2.2. Retail Pharmacies
- 7.2.3. Others
Chapter 8. Global Anti-radiation Drugs Market Size & Forecasts by Region 2022-2032
- 8.1. North America Anti-radiation Drugs Market
- 8.1.1. U.S. Anti-radiation Drugs Market
- 8.1.1.1. Compound breakdown size & forecasts, 2022-2032
- 8.1.1.2. Application breakdown size & forecasts, 2022-2032
- 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Anti-radiation Drugs Market
- 8.1.1. U.S. Anti-radiation Drugs Market
- 8.2. Europe Anti-radiation Drugs Market
- 8.2.1. Germany Anti-radiation Drugs Market
- 8.2.2. U.K. Anti-radiation Drugs Market
- 8.2.3. France Anti-radiation Drugs Market
- 8.2.4. Italy Anti-radiation Drugs Market
- 8.2.5. Rest of Europe Anti-radiation Drugs Market
- 8.3. Asia-Pacific Anti-radiation Drugs Market
- 8.3.1. China Anti-radiation Drugs Market
- 8.3.2. Japan Anti-radiation Drugs Market
- 8.3.3. India Anti-radiation Drugs Market
- 8.3.4. Rest of Asia-Pacific Anti-radiation Drugs Market
- 8.4. Latin America Anti-radiation Drugs Market
- 8.4.1. Brazil Anti-radiation Drugs Market
- 8.4.2. Mexico Anti-radiation Drugs Market
- 8.4.3 Rest of Latin America Anti-radiation Drugs Market
- 8.5. Middle East and Africa Anti-radiation Drugs Market
- 8.5.1. Saudi Arabia Anti-radiation Drugs Market
- 8.5.2. South Africa Anti-radiation Drugs Market
- 8.5.3. Rest of Latin America Anti-radiation Drugs Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Amgen Inc.
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. Anbex Inc.
- 9.3.3. Arco Pharmaceuticals LLC
- 9.3.4. BTG International Inc.
- 9.3.5. Cellphire, Inc.
- 9.3.6. Chrysalis BioTherapeutics, Inc.
- 9.3.7. Darnitsa
- 9.3.8. Enzychem Lifesciences Corporation
- 9.3.9. Humanetics Corporation
- 9.3.10. Mission Pharmacal Company
- 9.3.11. Myelo Therapeutics GmbH
- 9.3.12. Partner Therapeutics
- 9.3.13. Pluri Inc.
- 9.3.14. Emergent BioSolutions Inc.
- 9.3.15. Jubilant Life Sciences
- 9.3.1. Amgen Inc.
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
